The Business Research Company’s 2026 market reports feature advanced enhancements such as market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, delivering more actionable and strategically valuable research.

How Is The Neuromuscular Disorders Market’s Market Value Anticipated To Evolve From 2026 To 2030?

The market size for neuromuscular disorders has experienced significant growth over recent years. Projections indicate a rise from $8.31 billion in 2025 to $8.98 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 8.0%. This historical expansion is primarily due to factors such as the increasing prevalence of genetic neuromuscular conditions, greater awareness regarding early diagnosis and available treatment options, a heightened demand for effective therapies targeting rare disorders, increased research efforts in areas like muscular dystrophy and ALS, and the expanding implementation of advanced diagnostic technologies.

The neuromuscular disorders market size is projected to experience substantial growth in the coming years, with its value expected to reach $12.07 billion by 2030, expanding at a compound annual growth rate (CAGR) of 7.7%. This expansion during the forecast period is primarily driven by rising patient advocacy and support group activities, an increasing demand for biologics and gene therapies, greater recognition of neuromuscular disorders in pediatric cases, growing government initiatives focused on rare disease management, and an enhanced emphasis on home-based care and rehabilitation services. Key trends anticipated in this period include advancements in gene-editing technologies for targeted therapies, innovation in RNA-based treatment platforms, the integration of AI for more rapid neuromuscular diagnosis, progress in stem-cell-based regenerative treatments, and new developments in wearable devices for continuous patient monitoring.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=30678&type=smp

Which Drivers Are Advancing The Neuromuscular Disorders Market Growth?

The increasing need for personalized medicine is projected to stimulate the expansion of the neuromuscular disorders market in the future. This medical approach focuses on customizing treatments for individual patients, considering their unique genetic, environmental, and lifestyle elements to achieve the best possible outcomes and enhance patient care. Growth in genomic technologies, allowing for accurate identification of genetic variations and personalized treatment development, is fueling the rise in demand for personalized medicine. It improves the management of neuromuscular disorders by customizing therapies according to each patient’s specific genetic, molecular, and physiological characteristics. This approach leads to better patient results through targeted interventions, maximizing effectiveness, and reducing unwanted side effects. For example, in February 2024, the Personalized Medicine Coalition (PMC), a US-based nonprofit organization, reported that the U.S. Food and Drug Administration (FDA) authorized 26 novel personalized medicines in 2023, marking a considerable rise from the 12 approved in 2022. Consequently, the escalating demand for personalized medicine is a key factor propelling the expansion of the neuromuscular disorders market.

How Is Segment Classification Applied In The Neuromuscular Disorders Market?

The neuromuscular disorders market covered in this report is segmented –

1) By Disease Type: Spinal Muscular Atrophy (SMA), Amyotrophic Lateral Sclerosis (ALS), Duchenne Muscular Dystrophy (DMD), Myasthenia Gravis, Other Muscular Dystrophies

2) By Product Type: Pharmaceuticals, Biologics, Diagnostic Tools, Assistive Devices

3) By Route of Administration: Oral, Injectable, Other Route of Administrations

4) By Treatment: Gene Therapy, Drug Therapy, RNA-Based Therapy, Enzyme Replacement Therapy, Physical Therapy And Rehabilitation, Respiratory Care

Subsegments:

1) By Spinal Muscular Atrophy: SMA Type 1, SMA Type 2, SMA Type 3, SMA Type 4, SMA with Respiratory Distress (SMARD)

2) By Amyotrophic Lateral Sclerosis: Sporadic ALS, Familial ALS, Limb-Onset ALS, Bulbar-Onset ALS, Respiratory-Onset ALS

3) By Duchenne Muscular Dystrophy: Early-Onset DMD, Late-Onset DMD, Exon Deletion Mutations, Exon Duplication Mutations, Point Mutations

4) By Myasthenia Gravis: Generalized Myasthenia Gravis, Ocular Myasthenia Gravis, Seropositive MG, MuSK-Positive MG, Seronegative MG

5) By Other Muscular Dystrophies: Becker Muscular Dystrophy (BMD), Limb-Girdle Muscular Dystrophy (LGMD), Facioscapulohumeral Muscular Dystrophy (FSHD), Congenital Muscular Dystrophies, Myotonic Dystrophy

What Trends Are Affecting The Growth Of The Neuromuscular Disorders Market?

Leading companies operating within the neuromuscular disorders market are concentrating on creating innovative therapies, such as gene replacement treatments, to address the foundational genetic causes of conditions like Duchenne muscular dystrophy and spinal muscular atrophy. Gene replacement therapy involves engineered biological agents designed to introduce functional copies of defective genes, aiming to restore or improve muscle function in patients with inherited neuromuscular conditions, thereby presenting a potential single-dose solution that could lessen the requirement for ongoing chronic treatment. For instance, in November 2025, Novartis, a Switzerland-based pharmaceuticals company, obtained approval from the US Food and Drug Administration (FDA) for Itvisma (onasemnogeneabeparvovec-brve). This product represents the initial and sole gene replacement therapy approved for treating children two years of age and older, teenagers, and adults diagnosed with spinal muscular atrophy (SMA) who possess a confirmed mutation in the survival motor neurone 1 (SMN1) gene. Itvisma is specifically formulated to address the genetic root cause of SMA with a singular, consistent dosage that does not necessitate adjustments based on body weight or age. By substituting the SMN1 gene, Itvisma has the potential to improve motor function, which may subsequently reduce the need for long-term medication traditionally used in conjunction with other existing treatments for this patient group.

Which Key Players Are Active In The Neuromuscular Disorders Market?

Major companies operating in the neuromuscular disorders market are AbbVie Inc., Novartis AG, Takeda Pharmaceutical Company Limited, The Trustees of the University of Pennsylvania, Biogen Inc., Sarepta Therapeutics Inc., argenx SE, PTC Therapeutics Inc., Catalyst Pharmaceuticals Inc., Mayo Clinic Laboratories, Fulgent Genetics Inc., Dyne Therapeutics Inc., The Regents of the University of California, GeneDx LLC, PepGen Inc., Centogene N.V., Scholar Rock Holding Corporation, Solid Biosciences Inc., Vita Therapeutics Inc., NMD Pharma A/S, Cytokinetics Incorporated, Sudo Biosciences Inc.

Access The Complete Neuromuscular Disorders Market Report:

https://www.thebusinessresearchcompany.com/report/neuromuscular-disorders-market-report

Which Region Leads The Neuromuscular Disorders Market By Size?

North America was the largest region in the neuromuscular disorders market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the neuromuscular disorders market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Access a Customized Neuromuscular Disorders Market Report for Deeper Competitive Insights

https://www.thebusinessresearchcompany.com/sample.aspx?id=30678&type=smp

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model